Cargando…

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

OBJECTIVE: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3–4) enrolled in clinical trials. RESEARCH DESIGN AND METHODS: This analysis pooled data from 19 randomized, placebo-controlled, phase 1–4 clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tuttle, Katherine R., Levin, Adeera, Nangaku, Masaomi, Kadowaki, Takashi, Agarwal, Rajiv, Hauske, Sibylle J., Elsäßer, Amelie, Ritter, Ivana, Steubl, Dominik, Wanner, Christoph, Wheeler, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2022
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210861/ https://www.ncbi.nlm.nih.gov/pubmed/35472672 http://dx.doi.org/10.2337/dc21-2034

Ejemplares similares

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
por: Bramlage, Peter, et al.
Publicado: (2020)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women
por: Yoshida, Yilin, et al.
Publicado: (2021)

Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
por: Shestakova, Marina, et al.
Publicado: (2023)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
por: Rossing, Peter, et al.
Publicado: (2022)

Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial
por: Ueki, Kohjiro, et al.
Publicado: (2016)

Effect of vitamin D(3) supplementation on glycated hemoglobin (HbA1c), fructosamine, serum lipids, and body mass index: a randomized, double-blinded, placebo-controlled trial among healthy immigrants living in Norway
por: Madar, Ahmed A, et al.
Publicado: (2014)

Noninvasive Evaluation of Neural Impairment in Subjects With Impaired Glucose Tolerance
por: Putz, Zsuzsanna, et al.
Publicado: (2009)

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study
por: de Ritter, Rianneke, et al.
Publicado: (2019)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
por: Thirunavukarasu, Sharmaine, et al.
Publicado: (2021)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Prevalence of the Metabolic Syndrome Among a Racially/Ethnically Diverse Group of U.S. Eighth-Grade Adolescents and Associations With Fasting Insulin and Homeostasis Model Assessment of Insulin Resistance Levels
Publicado: (2008)

Glucose Intolerance in Pregnancy and Future Risk of Pre-Diabetes or Diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2008)

Changes in Triglyceride Levels Over Time and Risk of Type 2 Diabetes in Young Men
por: Tirosh, Amir, et al.
Publicado: (2008)

Risk Prediction of Cardiovascular Disease in Type 2 Diabetes: A risk equation from the Swedish National Diabetes Register
por: Cederholm, Jan, et al.
Publicado: (2008)

Changes in Risk Variables of Metabolic Syndrome Since Childhood in Pre-Diabetic and Type 2 Diabetic Subjects: The Bogalusa Heart Study
por: Nguyen, Quoc Manh, et al.
Publicado: (2008)

Alcohol Consumption, Mediating Biomarkers, and Risk of Type 2 Diabetes Among Middle-Aged Women
por: Beulens, Joline W.J., et al.
Publicado: (2008)

Predicting Diabetes: Clinical, Biological, and Genetic Approaches: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR)
por: Balkau, Beverley, et al.
Publicado: (2008)

Normal Glucose Values Are Associated With a Lower Risk of Mortality in Hospitalized Patients
por: Bruno, Alberto, et al.
Publicado: (2008)

Hyperinsulinemia in African-American Adolescents Compared With Their American White Peers Despite Similar Insulin Sensitivity: A reflection of upregulated β-cell function?
por: Hannon, Tamara S., et al.
Publicado: (2008)

Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program
por: Perreault, Leigh, et al.
Publicado: (2008)

Retinol-Binding Protein 4 and Insulin Resistance in Polycystic Ovary Syndrome
por: Hutchison, Samantha K., et al.
Publicado: (2008)

Insulin Resistance and Hyperinsulinemia: You can't have one without the other
por: Kim, Sun H., et al.
Publicado: (2008)

Tumor Necrosis Factor-α Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome
por: Tesauro, Manfredi, et al.
Publicado: (2008)

Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S.
por: Hoang, Khiet C., et al.
Publicado: (2008)

Association of Intrauterine Exposure to Maternal Diabetes and Obesity With Type 2 Diabetes in Youth: The SEARCH Case-Control Study
por: Dabelea, Dana, et al.
Publicado: (2008)

Assessment of Aortic Pulse Wave Velocity and Cardiac Diastolic Function in Subjects With and Without the Metabolic Syndrome: HDL cholesterol is independently associated with cardiovascular function
por: Roes, Stijntje D., et al.
Publicado: (2008)

Adipokines and Incident Type 2 Diabetes in a Canadian Aborigine Population: The Sandy Lake Health and Diabetes Project
por: Ley, Sylvia H., et al.
Publicado: (2008)

Subsequent Pregnancy After Gestational Diabetes Mellitus: Frequency and risk factors for recurrence in Korean women
por: Kwak, Soo Heon, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_s2i5a18mb6ev5aoha6qa7dg1ek